Learn about BYDUREON, a non-insulin treatment option for adults with type 2 diabetes available in the BYDUREON Pen. Find dosing and administration information for BYDUREON, including instructions for use. Learn about BYDUREON® BCise® including efficacy, safety, PK profile, and dosing, and available resources, including Important Safety Information.

Author: Zulujin Shaktijora
Country: Australia
Language: English (Spanish)
Genre: Sex
Published (Last): 11 March 2009
Pages: 277
PDF File Size: 10.7 Mb
ePub File Size: 5.46 Mb
ISBN: 976-9-22739-313-7
Downloads: 66499
Price: Free* [*Free Regsitration Required]
Uploader: Daizil

A decreased dose of the antidiabetic agent may be necessary as inseet hypoglycemia has been reported in patients treated concomitantly with hydroxychloroquine and an antidiabetic agent.

Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. Finally, both thiazides and sulfonylureas have been reported to cause photosensitivity reactions; concomitant use may increase the risk of photosensitivity.

PDR Search

Moderate Thiazide diuretics can decrease insulin sensitivity thereby leading to glucose intolerance and hyperglycemia. Burns, diarrhea, fever, infection, surgery, thyroid disease, trauma, vomiting. Occupation of the GLP-1 receptor site by exenatide results in an increase in both glucose-dependent synthesis of insulin, and in vivo secretion of insulin from pancreatic beta cells in the presence of elevated glucose. Even if the disposable needle is changed, sharing may result in transmission of hepatitis viruses, HIV, or other blood-borne pathogens.

Artsana InsuPen 29G and 31G pen needles. Insedt acutely improves glycemic control by reducing fasting and postprandial glucose concentrations in patients with type 2 diabetes.

Exenatide must be well-suspended mixed prior to use from a pen or syringe kit.

Moderate Reserpine may mask the signs and symptoms of hypoglycemia. Consideration should be given to alternative antidiabetic therapy in patients with a history of pancreatitis. Acetaminophen AUC, Cmax, and Tmax were not significantly changed when acetaminophen was given 1 h before exenatide injection.

Exenatide is approved for use with basal insulin. Extended-release exenatide is not a first-line therapy for pafkage inadequately controlled on diet and exercise. Patients taking antidiabetic agents should be closely monitored for changes in glycemic control, specifically hyperglycemia, if protease inhibitor therapy is initiated.


Moderate A potential pharmacodynamic interaction exists between indapamide and antidiabetic agents, like incretin mimetics. Exenatide has not been found to be directly nephrotoxic in preclinical or clinical studies.

This interference can lead to a loss of diabetic control, so diabetic patients should be monitored closely if these drugs are initiated.

The mechanism of hyperglycemia is thought to be through direct beta-cell toxicity. Close monitoring of blood glucose is necessary for individuals who use antidiabetic agents whenever there is a change in thyroid treatment.

A green shield will pop up after the cap is removed; byureon green shield hides the needle. Indapamide can decrease insulin sensitivity thereby leading to glucose intolerance and hyperglycemia. Furthermore, tacrolimus has been implicated in causing insulin-dependent diabetes mellitus in patients after renal transplantation.

Close monitoring of blood glucose is recommended. Because blood glucose may be lowered packaage the use of chromium, patients who are on antidiabetic agents may need dose adjustments. Growth hormones, such as somatropin, may decrease insulin sensitivity, leading to glucose intolerance and loss of blood glucose control.

Extended-release exenatide has been shown to cause dose-dependent and treatment duration-dependent malignant thyroid C-cell tumors at clinically relevant exposures in both genders of rats. Serum glucose should be monitored closely when MAOIs are added to any regimen containing antidiabetic agents.

Bydureon (exenatide) dose, indications, adverse effects, interactions from

Hypoglycemia, sometimes resulting in coma, can occur. The hyperglycemic effect begins within an hour and generally lasts no more than 8 hours in the presence of normal renal function. Ethanol inhibits gluconeogenesis, which can contribute to or increase the risk for hypoglycemia. Patients should be monitored for worsening of glycemic control if therapy with cyclosporine is initiated in patients receiving antidiabetic agents, including incretin mimetics.

Diuretic-induced hypokalemia may also lead to hyperglycemia. The risk of hypoglycemia is increased when exenatide is used in combination with insulin secretagogues e. Patient and family education regarding hypoglycemia management is crucial; the patient and patient’s family should be instructed on how to recognize and manage the symptoms of hypoglycemia.


A reduction in dose of oral hypoglycemic medications may be required in some patients taking orlistat. Hemodialysis Exenatide is not recommended for use in patients with end-stage renal disease ESRD on continuous or intermittent hemodialysis.

Selective beta-blockers, such as atenolol or metoprolol, do not appear to potentiate insulin-induced hypoglycemia. Some incretin mimetics make specific recommendations to reduce the risk for interaction. Overall steady state AUC of digoxin was not altered. A Byetta Pen can be used for up to 30 days after first use. Bdureon of the potential for clinically significant adverse reactions from exenatide in byxureon infants, caution should be exercised, and a decision should be made whether to discontinue nursing or discontinue the drug, taking into account these potential risks against the glycemic benefits to the lactating woman.

Among patients with end-stage renal disease receiving dialysis, the mean exenatide exposure increased by 3.

Geriatric patients are budureon at risk for hypoglycemic episodes. For treatment of cold symptoms, nasal decongestants may be preferable for short term, limited use 1 to 3 days as an alternative to systemic decongestants in patients taking medications for diabetes.

Exenatide also slows gastric emptying thereby reducing the rate at which meal-derived glucose appears in the circulation. Nicotine activates neuroendocrine pathways e. Based on glucose monitoring and clinical response, may increase after 1 month to exenatide 10 mcg subcutaneously twice daily.

After 30 days, throw away the pen, even if some medicine remains in it.

After that, patients can resume their usual dosing schedule of once every 7 days weekly.